Evaluation of brain-targeted chitosan nanoparticles through blood–brain barrier cerebral microvessel endothelial cells

References

• Akagi J, Kordon M, Zhao H, Matuszek A, Dobrucki J, Errington R, Smith PJ, Takeda K, Darzynkiewicz Z, Wlodkowic D. Real-time cell viability assays using a new anthracycline derivative DRAQ7®. Cytometry A, 2013;83A:227–34.
   Web of Science ®Google Scholar
• Aktaş Y, Yemisci M, Andrieux K, Gürsoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R, Sargon MF, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem, 2005;16:1503–11.
   PubMed Web of Science ®Google Scholar
• Aparicio-Blanco J, Martín-Sabroso C, Torres-Suárez A-I. In vitro screening of nanomedicines through the blood brain barrier: A critical review. Biomaterials, 2016;103:229–55.
   PubMed Web of Science ®Google Scholar
• Bugnicourt L, Ladavière C. Interests of chitosan nanoparticles ionically cross-linked with tripolyphosphate for biomedical applications. Prog Polym Sci, 2016;60:1–17.
   Web of Science ®Google Scholar
• Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Deliv Rev, 2012;64:640–65.
   PubMed Web of Science ®Google Scholar
• Chuah LH, Billa N, Roberts CJ, Burley JC, Manickam S. Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. Pharm Dev Technol, 2013;18:591–9.
   PubMed Web of Science ®Google Scholar
• Clark AJ, Davis ME. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc Natl Acad Sci, 2015;112:12486–91.
   PubMed Web of Science ®Google Scholar
• Enriquez De Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, Vila A, Alonso MJ. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci, 2006;47:1416–25.
   PubMed Web of Science ®Google Scholar
• Gaudin A, Tagit O, Sobot D, Lepetre-Mouelhi S, Mougin J, Martens TF, Braeckmans K, Nicolas V, Desmaële D, De Smedt SC, et al. Transport mechanisms of squalenoyl-adenosine nanoparticles across the blood–brain barrier. Chem Mater, 2015;27:3636–47.
   Web of Science ®Google Scholar
• Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, Desimone JM. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA, 2008;105:11613–18.
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: Relevance to drug delivery. Cell Mol Life Sci, 2009;66:2873–96.
   PubMed Web of Science ®Google Scholar
• Hoemann CD, Guzman-Morales J, Tran-Khanh N, Lavallee G, Jolicoeur M, Lavertu M. Chitosan rate of uptake in HEK293 cells is influenced by soluble versus microparticle state and enhanced by serum-induced cell metabolism and lactate-based media acidification. Molecules, 2013;18:1015–35.
   PubMed Web of Science ®Google Scholar
• Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: Effects of molecular weight and degree of deacetylation. Pharm Res, 2004;21:344–53.
   PubMed Web of Science ®Google Scholar
• Huth U, Schubert R, Peschka-Süss R. 2006. Spectral imaging for the investigation of the intracellular fate of liposomes. Liposome technology, Volume II. Boca Raton, FL: Informa Healthcare, pp. 341–381.
   Google Scholar
• Jiang L, Li X, Liu L, Zhang Q. Cellular uptake mechanism and intracellular fate of hydrophobically modified pullulan nanoparticles. Int J Nanomedicine, 2013;8:1825–34.
   PubMed Web of Science ®Google Scholar
• Jonassen H, Kjøniksen A-L, Hiorth M. Stability of chitosan nanoparticles cross-linked with tripolyphosphate. Biomacromolecules, 2012;13:3747–56.
   PubMed Web of Science ®Google Scholar
• Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, Vural A, Pinarbasli O, Capan Y, Fernandez-Megia E, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood–brain barrier and provides neuroprotection. J Neurosci, 2009;29:13761–9.
   PubMed Web of Science ®Google Scholar
• Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev, 2010;62:3–11.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Mechanism of polymeric nanoparticle-based drug transport across the blood–brain barrier (BBB). J Microencapsul, 2013;30:49–54.
   PubMed Web of Science ®Google Scholar
• Ma Z, Lim LY. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: A comparison between chitosan molecules and chitosan nanoparticles. Pharm Res, 2003;20:1812–19.
   PubMed Web of Science ®Google Scholar
• Markoutsa E, Pampalakis G, Niarakis A, Romero IA, Weksler B, Couraud P-O, Antimisiaris SG. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm, 2011;77:265–74.
   PubMed Web of Science ®Google Scholar
• Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud P-O, Tuffin G, Drewe J, Huwyler J. The human brain endothelial cell line hCMEC/D3 as a human blood–brain barrier model for drug transport studies. J Neurochem, 2008;107:1358–68.
   PubMed Web of Science ®Google Scholar
• Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J, 2004;377:159–69.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release, 2010;145:182–95.
   PubMed Web of Science ®Google Scholar
• Sahin A, Esendagli G, Yerlikaya F, Caban-Toktas S, Yoyen-Ermis D, Horzum U, Aktas Y, Khan M, Couvreur P, Capan Y. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol, 2017. [Epub ahead of print]. DOI:10.1080/21691401.2016.1276924
   PubMed Web of Science ®Google Scholar
• Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release, 2016;235:34–47.
   PubMed Web of Science ®Google Scholar
• Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA, 1999;96:6775–80.
   PubMed Web of Science ®Google Scholar
• Thomsen P, Roepstorff K, Stahlhut M, Van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell, 2002;13:238–50.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm, 2009;71:251–6.
   PubMed Web of Science ®Google Scholar
• Weksler B, Romero IA, Couraud P-O. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS, 2013;10:16.
   PubMedGoogle Scholar
• Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. J Control Release, 2012;161:264–73.
   PubMed Web of Science ®Google Scholar
• Yemisci M, Caban S, Gursoy-Ozdemir Y, Lule S, Novoa-Carballal R, Riguera R, Fernandez-Megia E, Andrieux K, Couvreur P, Capan Y, Dalkara T. Systemically administered brain-targeted nanoparticles transport peptides across the blood–brain barrier and provide neuroprotection. J Cereb Blood Flow Metab, 2015;35:469–75.
   PubMed Web of Science ®Google Scholar
• Yemisci M, Gursoy-Ozdemir Y, Caban S, Bodur E, Capan Y, Dalkara T. Transport of a caspase inhibitor across the blood–brain barrier by chitosan nanoparticles. Methods Enzymol, 2012;508:253–69.
   PubMed Web of Science ®Google Scholar